Affiliations: [a] Department of Oncology, Wendeng Central Hospital of Weihai City, Weihai, Shandong, China | [b] Department of Radiology, Wendeng Central Hospital of Weihai City, Weihai, Shandong, China | [c] Department of Hepatobiliary Surgery, General Hospital of People's Liboration Army, Beijing, China
Correspondence:
[*]
Corresponding author: Shengjie Zhu, Department of Oncology, Wendeng Central Hospital of Weihai City, Weihai 264400, Shandong, China. Tel./Fax: +86 06318459545; E-mail: izhushengjie@163.com.
Abstract: Background:Ghrelin was associated with several of cancers. The conflict results of SNPs with GHRL and GHSR gene were demonstrated in different studies. Thus, this meta-analysis is to evaluate the associations. Methods:Systematic literature search was done on PubMed database up to October 2013. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association by a fixed-effect model and a random-effect model. Results:A total of 7 studies, which included 3 studies for breast cancer, 2 for colorectal cancer, 1 for hepatocellular carcinoma, 1 for esophageal cancer and 1 for Non-Hodgkin lymphoma. When analyzed all the GHRL SNPs with all kinds of cancers, there was significantly difference with cancer patients compared with controls (Recessive model: OR 0.938, 95% CI 0.890–0.989, p=0.017), while no significant difference was existed in the additive model (OR 0.9903, 95% CI 0.957–1.024, p=0.558) and dominant model (OR 1.014, 95% CI 0.970–1.061, p=0.536). When analyzed all the GHSR SNPs with all kinds of cancers, no significant difference was observed. Conclusion:Our results suggest that the SNP with GHRL and GHSR might be weaker association with cancer risk, especially with breast cancer risk.
